Interleukin-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by up-regulating manganese superoxide dismutase
Open Access
- 29 May 2012
- journal article
- research article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 444 (3), 515-527
- https://doi.org/10.1042/bj20112019
Abstract
IL (interleukin)-6, an established growth factor for multiple myeloma cells, induces myeloma therapy resistance, but the resistance mechanisms remain unclear. The present study determines the role of IL-6 in re-establishing intracellular redox homoeostasis in the context of myeloma therapy. IL-6 treatment increased myeloma cell resistance to agents that induce oxidative stress, including IR (ionizing radiation) and Dex (dexamethasone). Relative to IR alone, myeloma cells treated with IL-6 plus IR demonstrated reduced annexin/propidium iodide staining, caspase 3 activation, PARP [poly(ADP-ribose) polymerase] cleavage and mitochondrial membrane depolarization with increased clonogenic survival. IL-6 combined with IR or Dex increased early intracellular pro-oxidant levels that were causally related to activation of NF-κB (nuclear factor κB) as determined by the ability of N-acetylcysteine to suppress both pro-oxidant levels and NF-κB activation. In myeloma cells, upon combination with hydrogen peroxide treatment, relative to TNF (tumour necrosis factor)-α, IL-6 induced an early perturbation in reduced glutathione level and increased NF-κB-dependent MnSOD (manganese superoxide dismutase) expression. Furthermore, knockdown of MnSOD suppressed the IL-6-induced myeloma cell resistance to radiation. MitoSOX Red staining showed that IL-6 treatment attenuated late mitochondrial oxidant production in irradiated myeloma cells. The present study provides evidence that increases in MnSOD expression mediate IL-6-induced resistance to Dex and radiation in myeloma cells. The results of the present study indicate that inhibition of antioxidant pathways could enhance myeloma cell responses to radiotherapy and/or chemotherapy.Keywords
This publication has 69 references indexed in Scilit:
- Manipulation of cellular redox parameters for improving therapeutic responses in B‐cell lymphoma and multiple myelomaJournal of Cellular Biochemistry, 2011
- Crosstalk of reactive oxygen species and NF-κB signalingCell Research, 2010
- Hydroethidine- and MitoSOX-derived red fluorescence is not a reliable indicator of intracellular superoxide formation: Another inconvenient truthFree Radical Biology & Medicine, 2010
- Lymphoma and Myeloma Cell Resistance to Cytotoxic Agents and Ionizing Radiations Is Not Affected by Exposure to Anti–IL-6 AntibodyPLOS ONE, 2009
- HPLC study of oxidation products of hydroethidine in chemical and biological systems: ramifications in superoxide measurementsFree Radical Biology & Medicine, 2009
- Interleukin-6 Mediates the Increase in NADPH-Oxidase in the Ketamine Model of SchizophreniaJournal of Neuroscience, 2008
- Redox Regulation of Cell SurvivalAntioxidants and Redox Signaling, 2008
- Integrated molecular profiling of SOD2 expression in multiple myelomaBlood, 2006
- Selective fluorescent imaging of superoxide in vivo using ethidium-based probesProceedings of the National Academy of Sciences of the United States of America, 2006
- Oxidant/antioxidant parameters and their relationship with medical treatment in multiple myelomaCell Biochemistry and Function, 2004